GuruFocus.com14m fa · leggi qui →
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks
Investors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.…
Investor's Business Daily22m fa · leggi qui →
AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough?
AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb.…
Barrons.com2h fa · leggi qui →
Amazon, Apple, Boeing, Micron, Bristol Myers, GameStop, SpaceX, and More Stocks That Explain Today’s Market
FEATURE Stocks rallied Monday with new records in reach for the and after President Donald Trump said he would restart talks with Iran, bolstering investors’ hopes of a cease-fire in the Middle East.…
Barrons.com2h fa · leggi qui →
Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billi…
MT Newswires2h fa · leggi qui →
Update: US Equity Indexes Rise Amid Rally in Communication Services; Crude Oil Slides With Treasury Yields
US equity indexes rose after midday Monday amid strong gains in communications services, while a sli…
Zacks3h fa · leggi qui →
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?…
The Wall Street Journal3h fa · leggi qui →
Stocks to Watch: Bristol Myers Squibb, Alibaba, Palantir
↘️AstraZeneca (AZN, UK:AZN), Bristol Myers Squibb (BMY): The drug companies are in talks to combine in a deal that would value the joint company at roughly $400 billion, the Financial Times reported. …
Moby3h fa · leggi qui →
AstraZeneca Eyes a Pharma Megamerger Nobody Asked For
The UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.…
24/7 Wall St.3h fa · leggi qui →
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.…
Bloomberg4h fa · leggi qui →
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intellige…